Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer’s Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine
Restricted accessResearch articleFirst published online March 15, 2016
Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer’s Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine
The endogenous cannabinoid system represents a promising therapeutic target to modify neurodegenerative pathways linked to Alzheimer’s disease (AD). The aim of the present study was to evaluate the specific contribution of CB2 receptor to the progression of AD-like pathology and its role in the positive effect of a cannabis-based medicine (1:1 combination of Δ9-tetrahidrocannabinol and cannabidiol) previously demonstrated to be beneficial in the AβPP/PS1 transgenic model of the disease. A new mouse strain was generated by crossing AβPP/PS1 transgenic mice with CB2 knockout mice. Results show that lack of CB2 exacerbates cortical Aβ deposition and increases the levels of soluble Aβ40. However, CB2 receptor deficiency does not affect the viability of AβPP/PS1 mice, does not accelerate their memory impairment, does not modify tau hyperphosphorylation in dystrophic neurites associated to Aβ plaques, and does not attenuate the positive cognitive effect induced by the cannabis-based medicine in these animals. These findings suggest a minor role for the CB2 receptor in the therapeutic effect of the cannabis-based medicine in AβPP/PS1 mice, but also constitute evidence of a link between CB2 receptor and Aβ processing.
CabralGA, RabornES, GriffinL, DennisJ, Marciano-CabralF (2008) CB2 receptors in the brain: Role in central immune function. Br J Pharmacol153, 240–251.
2.
BenitoC, TolónRM, PazosMR, NúñezE, CastilloAI, RomeroJ (2010) Cannabinoid CB2 receptors in human brain inflammation. Br J Pharmacol153, 277–285.
3.
Van SickleMD, DuncanM, KingsleyPJ, MouihateA, UrbaniP, MackieK, StellaN, MakriyannisA, PiomelliD, DavisonJS, MarnettLJ, Di MarzoV, PittmanQJ, PatelKD, SharkeyKA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science310, 329–332.
4.
ViscomiMT, OddiS, LatiniL, PasquarielloN, FlorenzanoF, BernardiG, MolinariM, MaccarroneM (2009) Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci29, 4564–4570.
5.
AtwoodBK, MackieK (2010) CB2: A cannabinoid receptor with an identity crisis. Br J Pharmacol160, 467–479.
6.
CallénL, MorenoE, Barroso-ChineaP, Moreno-DelgadoD, CortésA, MallolJ, CasadóV, LanciegoJL, FrancoR, LluisC, CanelaEI, McCormickPJ (2012) Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem287, 20851–20865.
7.
ZhangHY, GaoM, LiuQR, BiGH, LiX, YangHJ, GardnerEL, WuJ, XiZX (2014) Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A111, E5007–E5015.
8.
DhopeshwarkarA, MackieK (2014) CB2 Cannabinoid receptors as a therapeutic target— what does the future hold?. Mol Pharmacol86, 430–437.
9.
FerrerI (2012) Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. Prog Neurobiol97, 38–51.
BenitoC, NúñezE, TolónRM, CarrierEJ, RábanoA, HillardCJ, RomeroJ (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains. J Neurosci23, 11136–11141.
12.
RamírezBG, BlázquezC, Gómez del PulgarT, GuzmánM, de CeballosML (2005) Prevention of Alzheimer’s disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci25, 1904–1913.
13.
SolasM, FrancisPT, FrancoR, RamírezMJ (2013) CB2 receptor and amyloid pathology in frontal cortex of Alzheimer’s disease patients. Neurobiol Aging34, 805–808.
14.
SavonenkoAV, MelnikovaT, WangY, RavertH, GaoY, KoppelJ, LeeD, PletnikovaO, ChoE, SayyidaN, HiattA, TroncosoJ, DaviesP, DannalsRF, PomperMG, HortiAG (2015) Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: Immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation. PLoS One10, e0129618.
15.
TolónRM, NúñezE, PazosMR, BenitoC, CastilloAI, Martínez-OrgadoJA, RomeroJ (2009) The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages. Brain Res1283, 148–154.
WuJ, BieB, YangH, XuJJ, BrownDL, NaguibM (2013) Activation of the CB2 receptor system reverses amyloid-induced memory deficiency. Neurobiol Aging34, 791–804.
18.
van der SteltM, MazzolaC, EspositoG, MatiasI, PetrosinoS, De FilippisD, MicaleV, SteardoL, DragoF, IuvoneT, Di MarzoV (2006) Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: Effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci63, 1410–1424.
19.
EspositoG, IuvoneT, SavaniC, ScuderiC, DeD, Papa FilippisM, Di MarzoV, SteardoL (2007) Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: In vitro and in vivo evidence. J Pharmacol Exp Ther322, 1144–1152.
20.
FakhfouriG, AhmadianiA, RahimianR, GrollaAA, MoradiF, HaeriA (2012) WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway. Neuropharmacology63, 653–666.
KoppelJ, VingtdeuxV, MarambaudP, d’AbramoC, JimenezH, StauberM, FriedmanR, DaviesP (2014) CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer’s disease. Mol Med20, 29–36.
23.
AsoE, Sánchez-PlaA, Vegas-LozanoE, MaldonadoR, FerrerI (2015) Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. J Alzheimers Dis43, 977–991.
24.
CasarejosMJ, PeruchoJ, GómezA, MuñozMP, Fernández-EstévezM, SagredoO, Fernández-RuizJ, GuzmánM, de YébenesJG, MenaMA (2013) Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. J Alzheimers Dis35, 525–539.
25.
CaoC, LiY, LiuH, BaiG, MaylJ, LinX, SutherlandK, NabarN, CaiJ (2014) The potential therapeutic effects of THC on Alzheimer’s disease. J Alzheimers Dis42, 973–984.
26.
Martín-MorenoAM, ReigadaD, RamírezBG, MechoulamR, InnamoratoN, CuadradoA, de CeballosML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer’s disease. Mol Pharmacol79, 964–973.
27.
ChengD, LowJK, LoggeW, GarnerB, KarlT (2014) Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1ΔE9 mice. Psychopharmacology (Berl)231, 3009–3017.
28.
ChengD, SpiroAS, JennerAM, GarnerB, KarlT (2014) Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice. J Alzheimers Dis42, 1383–1396.
29.
HuestisMA (2005) Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol168, 657–690.
30.
PertweeRG (2008) The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydro-cannabivarin. Br J Pharmacol153, 199–215.
